Immuron Ltd — Investor Presentation 2014

Jun 4, 2014

2014 INVESTOR Chief Executive Officer Amos Meltzer

C. DIFF SUMMARY

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

2

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

C. DIFF
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

• A revenue generating product for preventing traveller’s diarrhoea

• A Phase II clinical product for treating liver disease – an unmet medical need

• Targeting the human immune system with natural antibodies derived from bovine colostrum to address diseases of the gut and liver

3

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [175 x 25] intentionally omitted <==

----- Start of picture text -----

C. DIFF SUMMARY
----- End of picture text -----

Indication Research Pre-clinical Phase I

Phase II Phase III

Traveller’s Diarrhoea

NASH

(IMM-124E)

ASH

(IMM-124E)

• Trial funded by NIH

Clostridium difficile infection

Other Projects:

• Related to Liver

4

• Related to IMM-124E

• And other indications

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

C. DIFF
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

• Attractive risk-reward ratio – biotech upside with reduced risk profile

Immuron’s Platform Products Other Products

• Natural product � Synthetic product

• Rapid Development Cycle � Longer and substantially more costly development

• Not a binary outcome. � Binary outcome: clinical trial failure means there is no product

• If clinical end points not attained, there is still a product that generates revenue

• Does not suppress immunity � Can suppress immunity

• Polyclonal Abs combat infectious � Monoclonal Abs are strain specific diseases effectively

• Multiple regulatory pathways

• Ordinarily: one regulatory pathway

5

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [175 x 25] intentionally omitted <==

----- Start of picture text -----

C. DIFF SUMMARY
----- End of picture text -----

Securities Currently on Issue

Shares Listed Options Unlisted Options Market Cap (AUD) Share Price (AUD)

* Note: 337,694,494 of options listed above are exercisable at more than a 100% premium to current share price.

6

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

C. DIFF
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Chairman

Non-executive Director

Non-executive Director

Chief Executive Officer

Clinical Director

Dr. Yaron Ilan Medical Officer

Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles.

Development Manager

Manufacturing Quality Director

2.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
Stop diarrhoea
BEFORE it starts
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

C. DIFF
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Traveller’s diarrhoea market estimated between US$600M and 1.2B globally All-natural product; clinically proven science with very high safety profile Available over-the-counter

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

Available over-the-counter
Unique: The only oral
therapy which prevents
Without Travelan [®] With Travelan [®] travellers’ diarrhoea
Bacteria releasing Bacteria neutralised by
diarrhoea-causing toxins in gut Travelan [®] antibodies
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [175 x 25] intentionally omitted <==

----- Start of picture text -----

C. DIFF SUMMARY
----- End of picture text -----

Increasing sales; improved margins

==> picture [177 x 119] intentionally omitted <==

10

==> picture [439 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW TRAVELAN NASH C. DIFF SUMMARY
----- End of picture text -----

Successful Australian brand, now going global

==> picture [721 x 416] intentionally omitted <==

----- Start of picture text -----

Proceeding through
regulatory process
Approved
In discussion
In discussion
In discussion
Proceeding
Licensed through
regulatory
process
In discussion
Licensed
Proceeding
through
regulatory
process
In Market
----- End of picture text -----

3.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

NASH / ASH
(INFLAMED
FATTY LIVER)
----- End of picture text -----

OVERVIEW

TRAVELAN

C. DIFF

SUMMARY

Worsening disease condition

Fatty Liver:

NASH/ Inflamed Fatty Liver

Liver Fibrosis:

Cirrhosis:

1 in 10 NASH patients develop liver cirrhosis; leads to liver cancer

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

NASH or inflamed fatty liver refers to a spectrum of chronic liver diseases
-
Closely associated with obesity, diabetes and high cholesterol
ASH is caused by excessive alcohol consumption
-
Poor prognosis leading to jaundice and liver failure
Currently no approved drug on market
----- End of picture text -----

OVERVIEW

TRAVELAN

C. DIFF

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

How Big is the Opportunity?

Intercept Pharmaceuticals (NASDAQ: ICPT) $1.5B before more than quadrupling overnight on NASH trial results

Market cap:

January 9, 2014: Announces successful results in NASH clinical trials

• There is a huge, unmet opportunity

• NASH on the radar

• Immuron may be best in class

Market cap: $1.5B

OVERVIEW

TRAVELAN

C. DIFF

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

NASH

ASH

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

The very large commercial opportunity Results from this trial expected to augment
NASH data package
IND cleared by FDA IND cleared by FDA
First clinical trials completed for NASH:
very encouraging results
Phase II trials to commence later this year Phase II trials to commence later this year
NIH funded, selected as 1 of 3 (from a possible
27) treatments to be funded by the NIH
----- End of picture text -----

4.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

C. DIFF
Treatment for
Superbug infections
----- End of picture text -----

OVERVIEW

TRAVELAN

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

US Hospitalisations Skyrocket Annually due to C.diff

• superbug

• more than US$3.2 billion in health care

==> picture [238 x 196] intentionally omitted <==

----- Start of picture text -----

346,800
85,700
----- End of picture text -----

Source: Agency for Healthcare Research and Quality

5.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

INVESTMENT
SUMMARY
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

TRAVELAN®

OVERVIEW

FATTY LIVER

1 Travelan[®]

– Sales growing and set to accelerate

• Revenue generating in Australia

• – Global expansion of Travelan[®] underway

• Large unmet medical need

• – Increasing investor and partnering focus

• – Phase I/IIa completed

• – IND cleared by FDA for Phase IIb commencing this year

2 Fatty liver/ NASH

Rich Product Pipeline

• Compelling Mechanism of Action

• – Applications to NASH, ASH and C.diff

3

4 Unique low-risk platform technology with marketable products at multiple inflection points 5 Strong balance sheet

4

Targeting the human immune system with natural antibodies derived from bovine colostrum to address diseases of the gut and liver

19

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

THANK YOU
----- End of picture text -----

By Chief Executive Officer Amos Meltzer ameltzer@immuron.com